DAIC

FEBRUARY 29, 2024

Session 104) - What Is Really New in Electrophysiology That Will Change My Practice? The Guidelines Sessions at ACC.24 24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m. 12:15 p.m.

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

EMS 12-Lead

AUGUST 22, 2022

Jesse McLaren @ECGcases [link] [link] This case was kindly submitted by Dr. Paco Dardon (@PacoDardon), and it’s a privilege to present it as a formal review due to the many pathophysiological, and electrophysiological, phenomenon at play. Indeed, bedside Echocardiogram revealed severe left ventricular impairment of Takotsubo cardiomyopathy.

Tachycardia 52

Tachycardia Cardiomyopathy Electrophysiology ICU 52

Cardiology Update

APRIL 9, 2024

Patients receiving semaglutide showed a greater change in Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary scores at 52 weeks than placebo. These patients were identified to have non-flow-limiting vulnerable coronary plaques through intracoronary imaging.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

EMS 12-Lead

JUNE 1, 2022

plaque disruption), the T waves still manifest markings of a previous state of suboptimal coronary flow that resolved: Type II supply-demand mismatch in the setting of extreme bradycardia. LBBB is typically the result of preexisting hypertrophy, ischemic heart disease, or cardiomyopathy. 6] Tabrizi, F., 7] Callans, D.

Heart Failure 52

Heart Failure Myocardial Infarction Bradycardia Chest Pain 52